Abstract:BACKGROUND Neuromyelitis optica (NMO) is a rare demyelinating disease of the central nervous system; NMO predominantly affects the spinal cord and optic nerves. The diagnosis is based on history, clinical presentation, seropositive NMO-IgG antibody, and notably, exclusion of other diseases. Despite the absence of definitive therapeutic strategies for NMO, methylprednisolone pulse therapy and plasma exchange are used for acute phase treatment, while immunosuppressive agent(s) are recommended to prevent relapses and improve prognosis. Here, we report a repeating relapse NMO case due to lack of regular and maintenance therapy. CASE REPORT A 58-year-old female with chronic NMO presented with a three-day history of new-onset right leg weakness and pain. The patient was diagnosed with NMO three years ago and presented with her fourth attacks. During her initial diagnosis, she was initiated on steroids. One year later, she developed the first relapse and was treated with steroids and rituximab, leading to 1.5-year remission. After the second relapse, steroids and rituximab was still given as maintenance therapy, but was not followed. Thus, the third relapse occurred in five months. During this hospitalization, she received initially high-dose solumedrol (1 g daily for five days) in addition to gabapentin 100 mg (gradually increased to 300 mg) three times a day for muscle spasms. Due to worsening of paresthesia and hemiparesis, it was decided to place her on plasma exchange treatment. After two plasma exchanges, the patient's condition was improved and she regained strength in her lower extremity. She completed five more cycles of plasma exchange, and was then discharged on steroid therapy (prednisone 20 mg daily for 10 days then taper) as maintenance therapy and with follow-up in neurology clinic. CONCLUSIONS Over the span of three years, the patient has had three relapses since her NMO diagnosis where her symptoms have worsened. Steroid therapy alone seemed not insufficient in managing her more recent relapses. Nonadherence to NMO treatment likely increased her risk for recurrence, thus regular and long-term maintenance therapy is imperative to delay the progression and prevent relapse in NMO.

Dynamic changes in patient admission and their disabilities in multiple sclerosis and neuromyelitis optica: A Japanese nationwide administrative data study

Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment

Inpatient care of neuromyelitis optica spectrum disorder in Germany: Nationwide analysis from 2010 to 2021

Prognostic factors associated with disability in a cohort of neuromyelitis optica spectrum disorder and MOG-associated disease from a nationwide Portuguese registry

Time to disability milestones and annualized relapse rates in NMOSD and MOGAD

Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database

Advances in disease-modifying therapy of neuromyelitis optica spectrum disorders

Effects of Immunotherapies and Prognostic Predictors in Neuromyelitis Optica Spectrum Disorder: a Prospective Cohort Study

Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder.

Long-term disability progression in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a retrospective analysis of 101 patients

Impact of comorbidities on relapsing rates of Neuromyelitis Optica Spectrum Disorders: Insights from a longitudinal study in Taiwan

Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features

HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data

Application progress of disease modifying drugs in neuromyelitis optica spectrum disorder

[Treatment and clinical management of patients with neuromyelitis optica and anti-aquaporin 4 antibody]

Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder

A study of therapeutic efficacy of mycophenolate mofetil in the treatment of multiple sclerosis ;and neuromyelitis optica

A quarter-century report on neuromyelitis optica spectrum disorder in Thailand: A single-center tertiary care cohort

Clinical and Ocular Manifestation of Neuromyelitis Optica and Multiple Sclerosis

The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China

Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case